Pharmacy Times

Advanced Approaches to Pediatric Fluid and Electrolyte Therapy: What Pharmacists Need to Know

The article outlines modern pediatric fluid and electrolyte therapy, emphasizing isotonic maintenance IV solutions to curb hyponatremia and detailing the Holliday‑Segar and BSA‑based calculation methods. It differentiates oral rehydration for mild‑to‑moderate dehydration from phased isotonic bolus and deficit‑plus‑maintenance IV regimens...

Evolving Frontline Treatment Strategies in Diffuse Large B-Cell Lymphoma

Frontline treatment of diffuse large B‑cell lymphoma (DLBCL) is shifting from traditional R‑CHOP toward targeted and bispecific antibody‑based regimens. The POLARIX phase‑3 trial demonstrated that Pola‑R‑CHP improves progression‑free survival, particularly in activated‑B‑cell (ABC) disease and older patients. Early phase studies...

Pembrolizumab-Induced Adrenal Insufficiency: Recognizing and Managing a Diagnostic Challenge in Adjuvant NSCLC Therapy

Pembrolizumab used as adjuvant therapy for NSCLC can cause central adrenal insufficiency, presenting with nonspecific fatigue, nausea, and hyponatremia. In a 67‑year‑old patient, a markedly low morning cortisol and suppressed ACTH confirmed the diagnosis within ten weeks of treatment. Prompt...

Cetirizine and Levocetirizine Withdrawal Pruritus: What Pharmacists Need to Know About the FDA’s New Safety Warning

The FDA will update labeling for cetirizine and levocetirizine to warn of a rare but serious withdrawal‑related pruritus that can emerge days after stopping long‑term use. More than 200 adverse‑event reports, primarily linked to cetirizine, describe severe itching requiring medical...

Insulin Affordability: Policies and Pharmacist Roles in Diabetes Management

Insulin’s list price has surged more than 300% over the past two decades, driven by a rebate‑heavy gross‑to‑net bubble and limited biosimilar competition. Pharmacy‑benefit managers (PBMs) dominate 79% of the market, using high‑list‑price rebates to secure formulary placement, which inflates...

After Refusal-to-File, FDA Reconsiders Moderna’s mRNA Flu Vaccine With Higher Bar for Seniors

TrumpRx Explained: Implications for Community Pharmacy Practice

From Coverage to Care: Medicaid Expansion’s Impact on Breast Cancer Outcomes